Project 2: Novel NeurosERMs and NeurosARMs for Protection Against Alzheimer Pathology Roberta Diaz Brinton, PhD, PI and Christian J. Pike, PhD, PI Our goal is to develop safe and efficacious alternative hormone therapies to prevent or delay late-onset age-associated Alzheimer's disease (AD). This proposal builds on our extensive knowledge of the mechanisms of estrogen and androgen action in brain and the extensive epidemiological data indicating that estrogen-based hormone therapy reduces the risk of developing AD and the emerging findings that androgen therapy can sustain cognitive function during aging. Basic science analyses of gonadal hormone action in neurons provide a mechanistic understanding for the healthy cell bias of hormone action. Studies proposed herein are a preclinical plan to translate our basic understanding of gonadal hormone mechanisms in brain into rationally designed molecules that will function as brain selective estrogen receptor modulators (NeurosERMs) and androgen receptor modulators (NeurosARMs). The proposed translational analyses build on several decades of basic science discovery that have established the solid foundation of predictive gonadal hormone outcomes in brain. It is on this foundation that we propose to develop innovative, safe and efficacious alternatives to hormone therapy to sustain neurological health and to prevent the dysfunction and pathology of late-onset age-associated AD.
Specific Aim I proposes in vitro screens of NeurosERM and NeurosARM candidate molecules for efficacy to induce markers of neuroprotection, neural defense, neural plasticity. Further, we will assess the ability of candidate NeurosERMs and NeurosARMs to reduce B-amyloid accumulation and tau hyperphosphorylation. Consistent with the mission of the USC ADRC, we will also evaluate indicators of vascular viability and integrity to access efficacy of NeurosERMs / sARMs to prevent vascular disease. Molecules that reach criterion for in vitro efficacy will move to in vivo testing in Aim II.
In Specific Aim II, we will evaluate efficacies of NeurosERM and NeurosARM candidate molecules in a transgenic mouse model of AD to 1) reduce levels of tau phosphorylation and B-amyloid accumulation;2) prevent cognitive deficits;3) protect against vascular injury;and 4) prevent proliferation in reproductive tissues.

Public Health Relevance

Abundant research at multiple levels indicates that estrogen- and androgen-based therapies in aging women and men, respectively, have therapeutic efficacy in reducing risk of Alzheimer and vascular diseases. This project will identify novel mimetics of estrogen (NeurosERMs) and androgens (NeurosARMs) for translational purposes that will protect the brain and vasculature but lack deleterious effects of reproductive tissues.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005142-29
Application #
8450815
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
29
Fiscal Year
2013
Total Cost
$199,475
Indirect Cost
$78,234
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Hernandez, Gerson; Zhao, Liqin; Franke, Adrian A et al. (2018) Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor ?-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women. Menopause 25:191-196
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Ho, Jean K; Nation, Daniel A; Alzheimer’s Disease Neuroimaging Initiative (2018) Neuropsychological Profiles and Trajectories in Preclinical Alzheimer's Disease. J Int Neuropsychol Soc 24:693-702
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826

Showing the most recent 10 out of 590 publications